Dr. Olufemi R. Ayeni, MD, PhD, FRCSC

Claim this profile

McMaster University

Studies Hip Arthroscopy
Studies Microfractures
2 reported clinical trials
3 drugs studied

Affiliated Hospitals

Image of trial facility.
McMaster University

Clinical Trials Olufemi R. Ayeni, MD, PhD, FRCSC is currently running

Image of trial facility.

AMIC Surgery

for Hip Cartilage Injury

This is a pilot multi-centre RCT of 40 patients (ages 18-55 years, inclusive) undergoing primary hip arthroscopy with a focal articular cartilage defect of the acetabulum to compare the effect of using autologous matrix-induced chondrogenesis (AMIC) in comparison to microfracture on hip function, health-related quality of life, hip pain, cartilage regeneration, health utility, and any adverse events at 2 years. Follow-up will occur at 6 weeks, 6 months, 12 months, 18 months, and 24 months post-surgery.
Recruiting1 award Phase 1
Image of trial facility.

Quadriceps vs. Hamstring Autograft

for ACL Rupture

To date, the use of the quadriceps tendon as an autograft option in primary paediatric Anterior Cruciate Ligament (ACL) reconstruction has not been well studied. The 2018 International Olympic Committee (IOC) Consensus Statement now outlines the quadriceps tendon as a possible autograft option. However, no Randomised Control Trial (RCT) has examined the efficacy of the quadriceps tendon autograft in primary paediatric ACL reconstruction compared to the historical "gold-standard" soft-tissue hamstring autograft in this population. In light of its evidence for favourable outcomes in the adult population, and the (albeit limited) evidence showing safety and promise in the paediatric population, clinical equipoise exists for assessing its impact on outcomes in paediatric patients at the index surgery. This is a parallel, international, multi-centre, blinded randomized controlled trial of 352 skeletally-immature (at the time of injury) patients (ages 10-18 years, inclusive) undergoing primary ACL reconstruction to compare the effect of autograft tendon choice (i.e. hamstring versus soft-tissue quadriceps) on the rates of ACL graft failure, return-to-sport, knee function, pain, health-related quality of life and health utility, psychological factors, range of motion and stability, and any other adverse events at 24 months.
Recruiting1 award N/A7 criteria

More about Olufemi R. Ayeni, MD, PhD, FRCSC

Clinical Trial Related2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Olufemi R. Ayeni, MD, PhD, FRCSC has experience with
  • Autologous Matrix-induced Chondrogenesis (AMIC)
  • Quadriceps Tendon Autograft
  • Soft Tissue Hamstring Autograft
Breakdown of trials Olufemi R. Ayeni, MD, PhD, FRCSC has run
Articular Cartilage Injury

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Olufemi R. Ayeni, MD, PhD, FRCSC specialize in?
Is Olufemi R. Ayeni, MD, PhD, FRCSC currently recruiting for clinical trials?
Are there any treatments that Olufemi R. Ayeni, MD, PhD, FRCSC has studied deeply?
What is the best way to schedule an appointment with Olufemi R. Ayeni, MD, PhD, FRCSC?
What is the office address of Olufemi R. Ayeni, MD, PhD, FRCSC?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security